NEW YORK, May 2, 2016 /PRNewswire/ -- Oncolytics
Biotech Inc. (TSX: ONC; OTCQX: ONCYF) CEO Brad Thompson was interviewed by OTC Markets
Group Inc. (OTCQX: OTCM) in its OTCQX® Video Series. The
series features one-on-one interviews with senior executives of
OTCQX companies as they showcase their businesses and investment
profiles.
In the interview, Dr. Thompson discusses:
- How Oncolytics Biotech is developing oncolytic viruses for the
treatment of certain types of cancer
- Clinical trial status update
- Outlook for 2016
- Experience on OTCQX
- Investment considerations
To watch the complete interview, visit OTC Markets Group's
YouTube page at https://youtu.be/-gMdQ8Jm10w.
Oncolytics Biotech is a biotechnology company focused on the
development of oncolytic viruses as a potential therapeutic for use
in a broad range of cancers. The company is conducting clinical
studies using REOLYSIN®, its proprietary formulation of the human
reovirus, in some of the most prevalent forms of the disease
including lung, colorectal, and pancreatic cancers. Oncolytics'
clinical program includes a number of human trials at a variety of
stages including a Phase III trial in head and neck cancers. The
company has advanced its product manufacturing and intellectual
property initiatives in parallel with its clinical development
program to support development of a commercial product.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best
Market, the OTCQB® Venture Market, and the Pink® Open Market for
10,000 U.S. and global securities. Through OTC Link® ATS, we
connect a diverse network of broker-dealers that provide liquidity
and execution services. We enable investors to easily trade through
the broker of their choice and empower companies to improve the
quality of information available for investors.
To learn more about how we create better informed and more
efficient markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
The information contained in this press release and in the
video to which it refers is provided "as is" for educational and
informational purposes only, and should not serve as the basis for
any trading or investing decisions. OTC Markets Group makes no
representations and disclaims all express, implied and statutory
warranties of any kind to any viewer or third party. Neither
OTC Markets Group nor any of its affiliates makes any endorsement
of any particular company, security, product or financial strategy,
and nothing contained in this video should be construed as
investment advice. Investors should undertake their own
diligence and carefully evaluate companies before investing.
Media Contact:
Saskia
Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428,
saskia@otcmarkets.com
Logo - http://photos.prnewswire.com/prn/20110118/MM31963LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/video-oncolytics-biotech-ceo-brad-thompson-interviewed-in-otcqx-video-series-300260324.html
SOURCE OTC Markets Group Inc.